Navigation Links
Antibody Helps Repair MS Nerve Damage
Date:10/10/2007

Promising results in mice need to be repeated in humans, experts say

WEDNESDAY, Oct. 10 (HealthDay News) -- Researchers say they've made new strides in harnessing the body's natural ability to reverse nerve damage wrought by multiple sclerosis.

According to the U.S. team, a single low dose of a human antibody administered to laboratory mice repaired myelin, the protective sheath that covers nerves. Multiple sclerosis wreaks havoc with the nervous system by stripping away this outer covering.

"This is an exciting first step in increasing our knowledge of repair in multiple sclerosis using a unique approach," said Patricia O'Looney, vice president of biomedical research programs at the National Multiple Sclerosis Society (NMSS) in New York City, which helped fund the research.

The findings were presented Tuesday at the annual meeting of the American Neurological Association, in Washington, D.C.

In healthy individuals, damage to myelin repairs itself naturally. But in people with MS and other disorders of the central nervous system, myelin repair occurs either slowly or not at all. As a result, the flow of information between the brain and the rest of the body is impaired, resulting in movement problems.

Some 400,000 people in the United States and 2.5 million people globally have been diagnosed with MS, most of them between the ages of 20 and 50, according to the NMSS.

"The challenge for researchers in trying to get a cure is, how do we repair myelin and restore function?" O'Looney said.

There is some evidence that cells that produce myelin are still present around damaged areas. As O'Looney put it, "The cells are already there, so how do you stimulate them to do what they're supposed to be doing?"

For this study, researchers at the Mayo Clinic in Rochester, Minn., genetically engineered a special antibody, called rHIgM22. This antibody binds to myelin and the surface of cells in the brain and spinal cord, prompting those cells to begin the process of remyelination.

The antibody is the first known compound to spur repair by acting within the central nervous system.

Laboratory mice that received a single dose of the antibody experienced remyelination that plateaued within five weeks.

When combined with a steroid (often prescribed for patients with MS), the antibody continued to promote remyelination, the research team said. Most human patients who might receive the antibody one day in the future will have already been treated with this steroid, they noted.

The antibodies did not appear to have any side effects, even at 4,000 times the minimal effective dose.

The Mayo team will eventually have to replicate the findings in humans before the concept can become an effective therapy, experts say.

"This approach is trying to use a naturally occurring molecule in our body in such a way that it binds to the cell and triggers signals within the cell to begin the repair process," O'Looney said. "This is a very exciting area of research in MS. How do you stimulate natural repair? How do you stimulate cells already there to repair the damage that's done? This is a unique, different way of approaching that, and it seems to be very successful in one of the animal models of MS."

More information

For more on multiple sclerosis, visit the National Multiple Sclerosis Society.



SOURCES: Patricia O'Looney, Ph.D., vice president, biomedical research programs, National Multiple Sclerosis Society, New York City; Oct. 9, 2007, presentation, American Neurological Association annual meeting, Washington, D.C.


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Stroke risk might be linked to antibody
2. Human Antibody That Can Block SARS
3. Therapeutic Monoclonal Antibody Production Is More Profitable Than Small Molecule Drugs
4. Cancer killing antibody effective against prostate cancer
5. Cuba Registers New Antibody
6. Single Sugar Enables Antibody to Treat Inflammation
7. Monoclonal Antibody based system for Anthrax detection
8. Monoclonal Antibody Reduces Exacerbations in Asthmatics
9. Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels
10. Antibody Therapy Prevents Type 1 Diabetes
11. New Antibody for EGFR Causes Lung Cancer Regression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... Viejo, California (PRWEB) , ... January 20, 2017 , ... ... easy to use inside of Final Cut Pro X," said Christina Austin - CEO ... on the RED Dragon. Utilizing the Dragon Sensor,TransFlare 4K Mystique lens flare and light ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and earnest tale ... each of his children. “The Angel” is the creation of published author, Marjorie Lund-Fontaine, ... City, and impassioned writer. , When asked of her new book, Marjorie says, “‘The ...
(Date:1/20/2017)... ... January 20, 2017 , ... ... Positive Expiratory Pressure (OPEP) device, was featured in a study indicating superior performance ... RRT-ACCS, FAARC, “Analysis of Three Oscillating Positive Expiratory Pressure Devices During Simulated ...
(Date:1/20/2017)... ... , ... “Knowledge is God’s Lighthouse”: a moving and colorful collection of ... the creation of published author, Gene Gaapf, a retired truck driver, and a long-time ... been writing since high school and have many different titles,” Gaapf mentions about his ...
(Date:1/19/2017)... ... 20, 2017 , ... Today, the Centers for Medicare & Medicaid Services (CMS) ... Payment Models (APMs) in 2017. Clinicians who participate in APMs are paid for the ... of the Administration’s effort to build a system that delivers better care and one ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... Jan. 20, 2017  Palladian Health, a leading ... the launch of an opioid management program which ... opioids and helps stem the growing tide of ... to treat chronic non-cancer pain (back pain, neck ... and lack of evidence regarding long-term effectiveness. ...
(Date:1/20/2017)... 2017 Avillion LLP, a co-developer and financier ... Weinberg , MD MBA as Chief Medical Officer. Dr Weinberg will ... . ... Weinberg has spent more than 17 years as a pharmaceutical and ... micro-cap biotech. Over the course of his career, he has interfaced ...
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Which areas are going to grow at the fastest ... 2026, assessing data, trends, opportunities and prospects. Our ... the most lucrative areas in the industry and the ... forecasted sales across the all the major categories of ...
Breaking Medicine Technology: